IQVIA Hldgs Analyst Ratings
Evercore ISI Adjusts Price Target on IQVIA Holdings to $270 From $230, Maintains Outperform Rating
TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $500 From $450, Maintains Buy Rating
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,030, Maintains Buy Rating
Buy Rating Affirmed for Vertex Pharmaceuticals Amid Strategic Acquisition and Strong CF Franchise Outlook
Piper Sandler Reaffirms Their Buy Rating on Biogen (BIIB)
Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
IQVIA Holdings: Strong Q2 Performance and Raised Annual Guidance Prompt 'Buy' Rating
Gilead Sciences: A Balanced Outlook With Steady HIV Performance and Oncology Challenges Justifying a Hold Rating
Barclays Sticks to Its Buy Rating for IQVIA Holdings (IQV)
IQVIA Holdings: Strong H2 Outlook With Buoyant TAS, RWE, and RDS Segments Driving Buy Rating
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)
Stifel Adjusts IQVIA Holdings' Price Target to $312 From $288
Vertex Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Price Target Raised to $220.00/Share From $150.00 by Cantor Fitzgerald
Gilead Sciences Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings